COMMON INITIAL DOSING REGIMENS

• Inject 30mcg-300mcg (10 units via insulin syringe) SQ in the evening.

MECHANISM OF ACTION

• Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) with a high affinity for the GHRH receptor. By stimulating the anterior pituitary gland, it enhances the release of endogenous GH, which subsequently raises insulin-like growth factor 1 (IGF-1) levels. The increase in IGF-1 contributes to reduced visceral fat, improved lipid profiles, and enhanced protein synthesis, which supports lean body mass. Tesamorelin is particularly effective in targeting fat redistribution, making it valuable for reducing abdominal adiposity.

COMMON SIDE EFFECTS

• Injection Site: Pain, redness, or swelling at the injection site.

• Metabolic: Transient increases in blood glucose levels, with occasional hyperglycemia reported, especially in patients predisposed to diabetes.

• Neurological: Headache, dizziness, and fatigue.

• Cardiovascular: Rarely, mild peripheral edema or hypertension may occur due to fluid retention.

• Severe Effects: Hypersensitivity reactions, including anaphylaxis, have been reported in rare cases. Long-term safety studies are limited but suggest a low risk of adverse effects in healthy individuals.

CONTRAINDICATIONS

• Absolute: Active malignancy or hypersensitivity to tesamorelin or its components.

• Relative: Patients with poorly controlled diabetes or significant cardiovascular disease should use caution due to the potential for metabolic disturbances. Tesamorelin is not recommended for pregnant or breastfeeding women.

COMPARISON WITH OTHER HGH SUPPORT MEDICATIONS

• Tesamorelin vs. Sermorelin: Tesamorelin is more targeted in its ability to reduce visceral adiposity, making it ideal for body composition goals. Sermorelin, on the other hand, provides broader systemic benefits, including muscle repair and improved energy.

• Tesamorelin vs. Ipamorelin: Tesamorelin’s primary effect is on fat reduction through IGF-1, whereas ipamorelin focuses on stimulating GH release without significant changes in IGF-1. Ipamorelin may be preferable for patients seeking mild GH stimulation without metabolic side effects.

• Tesamorelin vs. CJC-1295: CJC-1295 has an extended half-life, leading to sustained GH release, while tesamorelin’s effects are more acute and targeted. CJC-1295 may provide broader anti-aging benefits, while tesamorelin is superior for reducing central adiposity.

• Tesamorelin vs. Ibutamoren: Ibutamoren is an oral GH secretagogue that increases appetite significantly, which may be undesirable for patients managing fat loss. Tesamorelin’s subcutaneous administration avoids appetite stimulation and provides a more precise fat-reduction effect.

MORE INFORMATION

• FDA Safety Data Sheet can be found here.

• Sinha DK. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 [PubMed Link]

• Svensson J. Growth hormone secretagogues as therapeutic agents. Growth Horm IGF Res. 1999 [PubMed Link]

• Clemmons DR. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017 [PubMed Link]

• Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013 [PubMed Link]

• Stanley TL. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011 [PubMed Link] 

• Spooner LM. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012 [PubMed Link]

• Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011 https://pubmed.ncbi.nlm.nih.gov/21668043/

• Lake JE. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021 [PubMed Link]

• Wang Y. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opin Investig Drugs. 2009 [PubMed Link]

• Rahman F. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2022 [PubMed Link]

• González-Sales M. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet. 2015 [PubMed Link]

• Adrian S. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019 [PubMed Link]

• Falutz J. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008 [PubMed Link]

• Mateo MG. Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy. Expert Rev Endocrinol Metab. 2011 [PubMed Link]

• Bedimo R. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl). 2011 [PubMed Link]

• Sigalos JT. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017 [PubMed Link]

• Ferro P. Structure-activity relationship for peptídic growth hormone secretagogues. Drug Test Anal. 2017 [PubMed Link]